Comparison of Korean COPD guideline and GOLD initiative report in term of acute exacerbation

A validation study for Korean COPD guideline

Yong Il Hwang, Yong Bum Park, Yeon Mok Oh, Ji Hyun Lee, Tae Hyung Kim, Kwang Ha Yoo, Hyoung Kyu Yoon, Chin Kook Rhee, Deog Kyeom Kim, Kyeong Cheol Shin, Sang Yeub Lee, Ki Suck Jung

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The purpose of this study was to compare the Korean COPD guideline to GOLD consensus report in terms of acute exacerbation. A total of 361 patients were enrolled in this study, and 16.9% of them experienced acute exacerbation during the follow-up. A total of 6.3% of patients in GOLD A, 9.5% in GOLD B, 7.7% in GOLD C and 17.0% of GOLD D experienced exacerbation during the first year of follow-up, respectively (P=0.09). There was no one who experienced exacerbation during the first year of follow-up in the Korean group 'ga'. The 12-month exacerbation rates of Korean group 'na' and 'da' were 4.5% and 16.0%, respectively (P<0.001). We explore the experience of exacerbation in patients with change of their risk group after applying Korean COPD guideline. A total of 16.0% of the patients who were reclassified from GOLD A to Korean group 'da' experienced acute exacerbation,and 15.3% from GOLD B to Korean group 'da' experienced acute exacerbation. In summary, the Korean COPD guideline is useful to differentiate the high risk from low risk for exacerbation in terms of spirometry. This indicates that application of Korean COPD guideline is appropriate to treat Korean COPD patients.

Original languageEnglish
Pages (from-to)1108-1112
Number of pages5
JournalJournal of Korean Medical Science
Volume29
Issue number8
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Validation Studies
Chronic Obstructive Pulmonary Disease
Guidelines
Spirometry

Keywords

  • Assessment
  • COPD
  • Exacerbation
  • FEV1
  • Guidelines

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Comparison of Korean COPD guideline and GOLD initiative report in term of acute exacerbation : A validation study for Korean COPD guideline. / Hwang, Yong Il; Park, Yong Bum; Oh, Yeon Mok; Lee, Ji Hyun; Kim, Tae Hyung; Yoo, Kwang Ha; Yoon, Hyoung Kyu; Rhee, Chin Kook; Kim, Deog Kyeom; Shin, Kyeong Cheol; Lee, Sang Yeub; Jung, Ki Suck.

In: Journal of Korean Medical Science, Vol. 29, No. 8, 01.01.2014, p. 1108-1112.

Research output: Contribution to journalArticle

Hwang, Yong Il ; Park, Yong Bum ; Oh, Yeon Mok ; Lee, Ji Hyun ; Kim, Tae Hyung ; Yoo, Kwang Ha ; Yoon, Hyoung Kyu ; Rhee, Chin Kook ; Kim, Deog Kyeom ; Shin, Kyeong Cheol ; Lee, Sang Yeub ; Jung, Ki Suck. / Comparison of Korean COPD guideline and GOLD initiative report in term of acute exacerbation : A validation study for Korean COPD guideline. In: Journal of Korean Medical Science. 2014 ; Vol. 29, No. 8. pp. 1108-1112.
@article{3012d184c6e34f7283ec6435ab34757e,
title = "Comparison of Korean COPD guideline and GOLD initiative report in term of acute exacerbation: A validation study for Korean COPD guideline",
abstract = "The purpose of this study was to compare the Korean COPD guideline to GOLD consensus report in terms of acute exacerbation. A total of 361 patients were enrolled in this study, and 16.9{\%} of them experienced acute exacerbation during the follow-up. A total of 6.3{\%} of patients in GOLD A, 9.5{\%} in GOLD B, 7.7{\%} in GOLD C and 17.0{\%} of GOLD D experienced exacerbation during the first year of follow-up, respectively (P=0.09). There was no one who experienced exacerbation during the first year of follow-up in the Korean group 'ga'. The 12-month exacerbation rates of Korean group 'na' and 'da' were 4.5{\%} and 16.0{\%}, respectively (P<0.001). We explore the experience of exacerbation in patients with change of their risk group after applying Korean COPD guideline. A total of 16.0{\%} of the patients who were reclassified from GOLD A to Korean group 'da' experienced acute exacerbation,and 15.3{\%} from GOLD B to Korean group 'da' experienced acute exacerbation. In summary, the Korean COPD guideline is useful to differentiate the high risk from low risk for exacerbation in terms of spirometry. This indicates that application of Korean COPD guideline is appropriate to treat Korean COPD patients.",
keywords = "Assessment, COPD, Exacerbation, FEV1, Guidelines",
author = "Hwang, {Yong Il} and Park, {Yong Bum} and Oh, {Yeon Mok} and Lee, {Ji Hyun} and Kim, {Tae Hyung} and Yoo, {Kwang Ha} and Yoon, {Hyoung Kyu} and Rhee, {Chin Kook} and Kim, {Deog Kyeom} and Shin, {Kyeong Cheol} and Lee, {Sang Yeub} and Jung, {Ki Suck}",
year = "2014",
month = "1",
day = "1",
doi = "10.3346/jkms.2014.29.8.1108",
language = "English",
volume = "29",
pages = "1108--1112",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "8",

}

TY - JOUR

T1 - Comparison of Korean COPD guideline and GOLD initiative report in term of acute exacerbation

T2 - A validation study for Korean COPD guideline

AU - Hwang, Yong Il

AU - Park, Yong Bum

AU - Oh, Yeon Mok

AU - Lee, Ji Hyun

AU - Kim, Tae Hyung

AU - Yoo, Kwang Ha

AU - Yoon, Hyoung Kyu

AU - Rhee, Chin Kook

AU - Kim, Deog Kyeom

AU - Shin, Kyeong Cheol

AU - Lee, Sang Yeub

AU - Jung, Ki Suck

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The purpose of this study was to compare the Korean COPD guideline to GOLD consensus report in terms of acute exacerbation. A total of 361 patients were enrolled in this study, and 16.9% of them experienced acute exacerbation during the follow-up. A total of 6.3% of patients in GOLD A, 9.5% in GOLD B, 7.7% in GOLD C and 17.0% of GOLD D experienced exacerbation during the first year of follow-up, respectively (P=0.09). There was no one who experienced exacerbation during the first year of follow-up in the Korean group 'ga'. The 12-month exacerbation rates of Korean group 'na' and 'da' were 4.5% and 16.0%, respectively (P<0.001). We explore the experience of exacerbation in patients with change of their risk group after applying Korean COPD guideline. A total of 16.0% of the patients who were reclassified from GOLD A to Korean group 'da' experienced acute exacerbation,and 15.3% from GOLD B to Korean group 'da' experienced acute exacerbation. In summary, the Korean COPD guideline is useful to differentiate the high risk from low risk for exacerbation in terms of spirometry. This indicates that application of Korean COPD guideline is appropriate to treat Korean COPD patients.

AB - The purpose of this study was to compare the Korean COPD guideline to GOLD consensus report in terms of acute exacerbation. A total of 361 patients were enrolled in this study, and 16.9% of them experienced acute exacerbation during the follow-up. A total of 6.3% of patients in GOLD A, 9.5% in GOLD B, 7.7% in GOLD C and 17.0% of GOLD D experienced exacerbation during the first year of follow-up, respectively (P=0.09). There was no one who experienced exacerbation during the first year of follow-up in the Korean group 'ga'. The 12-month exacerbation rates of Korean group 'na' and 'da' were 4.5% and 16.0%, respectively (P<0.001). We explore the experience of exacerbation in patients with change of their risk group after applying Korean COPD guideline. A total of 16.0% of the patients who were reclassified from GOLD A to Korean group 'da' experienced acute exacerbation,and 15.3% from GOLD B to Korean group 'da' experienced acute exacerbation. In summary, the Korean COPD guideline is useful to differentiate the high risk from low risk for exacerbation in terms of spirometry. This indicates that application of Korean COPD guideline is appropriate to treat Korean COPD patients.

KW - Assessment

KW - COPD

KW - Exacerbation

KW - FEV1

KW - Guidelines

UR - http://www.scopus.com/inward/record.url?scp=84937553517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937553517&partnerID=8YFLogxK

U2 - 10.3346/jkms.2014.29.8.1108

DO - 10.3346/jkms.2014.29.8.1108

M3 - Article

VL - 29

SP - 1108

EP - 1112

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 8

ER -